Current perspectives on the management of hypertriglyceridemia

American Heart Journal

Volumn 140, Issue 2, 2000, Pages 232-240

  Miller, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CLOFIBRATE; CONJUGATED ESTROGEN; DEXTROTHYROXINE; EPADIL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033899952     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.108001     Document Type: Article

References (57)

1. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: A meta-analysis of population-based prospective studies
2. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence
3. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: Cellular aspects
4. Familial lipoprotein disorders in patients with premature coronary artery disease
5. Triglyceride and cholesterol rich lipoproteins have a differential effect on mild-moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
6. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts
7. Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial
8. An angiographic evaluation of the effects of bezafibrate on the progression of coronary artery disease in young male post-infarction patients. The bezafibrate coronary atherosclerosis intervention trial (BECAIT)
9. Clofibrate and niacin in coronary heart disease
10. Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin
11. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
12. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
14. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
15. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
16. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
18. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
19. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)
20. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
21. Relation of baseline lipids and lipid changes with gemfibrozil to cardiovascular endpoints in the VA-High Density Lipoprotein Intervention Trial (VA-HIT)
22. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease
23. Regular physical exercise and low-fat diet. Effects of progression of coronary artery disease
24. Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project
25. The effect of diet on plasma lipids, lipoproteins, and coronary heart disease
26. Intensive lifestyle changes for reversal of coronary heart disease
27. Differential effects of a saturated and NCEP II diet on the postprandial response to a fat load
28. Dietary ethanol is associated with reduced lipolysis of intestinally derived lipoproteins
29. Mediterranean diet, troditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study
30. N-3 fatty acids and lipoproteins: Comparison of results from human and animal studies
31. Are fish oils beneficial in the prevention and treatment of coronary artery disease?
32. Dietary supplemenation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
33. Effects of a modified, well-tolerated niacin regimen on serum total cholesterol, HDL cholesterol and the cholesterol to HDL ratio
34. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia
35. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia
36. Comparison of excretion of nicotinuric acid after ingestion of two controlled released nicotinic acid preparations in man
37. A comparison of the efficacy and toxic effects of sustained vs immediate release niacin in hypercholesterolemia patients
38. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid
39. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study
40. WHO Cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Final mortality follow-up
41. Peroxisome Proliferator activated receptors: A nuclear receptor signaling pathway in lipid physiology
42. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: A double-blind, placebo-controlled multicenter US study
43. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia
44. Comparisons of statins in hypertriglyceridemia
45. Effects of statins on triglyceride metabolism
46. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
47. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia
48. Fluvastatin with and without niacin for hypercholesterolemia
49. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin
50. Pravastatin and gemfi-brozil alone and in combination for the treatment of hypercholesterolemia
51. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
52. Summary of the second report of the National Cholesterol Education Program (NCEP) panel on detectian, evaluation and treatment of high blood cholesterol in adults
53. Guide to preventive cardiology for women
54. Normol triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study
55. Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk
56. Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase mediated changes in LDL-C density